viernes, 7 de diciembre de 2018

Aridis is Planning a Trial for Antibacterial Therapy AR-501 in CF Patients

Aridis is Planning a Trial for Antibacterial Therapy AR-501 in CF Patients

Cystic Fibrosis News Today



Aridis to Start Phase 1/2a Trial for Inhalable Antibacterial Therapy AR-501 in CF Patients

No hay comentarios:

Publicar un comentario